Protagenic Therapeutics Erases $6.3 Million in Liabilities to Advance Promising Depression Treatment

New York, Tuesday, 17 March 2026.
Today, Protagenic Therapeutics eliminated over $6.3 million in liabilities by finalizing its Phytanix separation, allowing the leaner company to focus exclusively on its upcoming Phase 2 clinical trials.